Scrutiny Grows of Drug Trials Abroad Wall Street Journal - Last year, two elderly patients died after Polish investigators enrolled them in a study of a bird-flu vaccine being developed by Novartis AG even though ...
Don?t let flu season catch you off guard Atlanta Journal Constitution, USA - Nov 27, 2008 Children ages 6 months to 8 years who have never been immunized need two doses, but one dose will suffice for all others. Two types of flu vaccine are ...
Higher dose vaccine could be more effective News 10 Now, NY - Nov 15, 2008 "The current flu vaccine is effective but it's not nearly as good as it can be particularly in older people," said Infectious Disease Specialist Dr. Ann ...
Flu shots still available Sequoyah County Times, OK - Nov 20, 2008 Hattaway said, ?The purchase cost of each dose of vaccine is almost $11, in addition to the costs of administering the vaccine. During these tight budget ...
Clinic lacks funding for flu shots Deseret News, UT - Nov 27, 2008 Fourth Street staff believe $10000 is needed to fund this year's flu vaccination program. Costs will cover the purchase of the vaccines and program medical ...
Flu shots for kids: Do they help? San Francisco Chronicle, USA - Nov 10, 2008 The Food and Drug Administration says there is no evidence to support this, but if parents are truly concerned about the preservative in a flu vaccine...
Egg Free Flu Vaccine KDRV, OR - Nov 18, 2008 The cell-culture system is also efficient, and 'ups' the amount of flu protein in the shot. "And there's some evidence that giving a higher dose stimulates ...
Source: Google News
Recent News and Articles on the Keywords: flu + niaid + dose Related to the article below (Last Update: 8/5/2008)
Experts: Pneumonia Was Real Killer in 1918 Flu Pandemic FOXNews - ... author of next month's article and NIAID director, told New Scientist. Although pneumonia was behind the majority of deaths, it was the "lethal" flu...
Vical Takes New Tack With Bird-Flu Vaccine Wall Street Journal - Jul 16, 2008 In Rockville, Md., Niaid grantee Novavax Inc. is collaborating with General Electric Co.'s GE Healthcare to develop a pandemic-flu vaccine that harnesses ...VICL
Global Warming Heats Up Need For Malaria Vaccine Says Expert Newswise (press release) - Jul 11, 2008 Dr. Fleury completed his postgraduate studies in Bethesda (USA) at the NIAID, National Institutes of Health (NIH), with world-renowned immunologist Dr. ...
Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus - TM Tumpey, CF Basler, PV Aguilar, H Zeng, A … - Science, 2005 - sciencemag.org ... time in days for the minimum lethal dose to kill ... CIVIA) (U19 AI62623), as well as
by NIAID grant P01 ... 1918 Flu and Responsible Science Phillip A. Sharp Science ...
Avian influenza vaccine clinical trial begins in USA - M Quirk - The Lancet Infectious Diseases, 2005 - Elsevier ... manufacturing delays, an investigational avian influenza A (H5N1 ... were awarded a contract
by NIAID to manufacture ... who received their first vaccine dose on April 4 ...
Vaccination Strategies for an Influenza Pandemic - B Schwartz, B Gellin - The Journal of Infectious Diseases, 2005 - UChicago Press ...Dose sparing with intradermal injection of influenza vaccine. ... Available at:
http://www2.niaid.nih.gov/newsroom ... news release: NNS orders avian flu vaccine doses ...
[PDF]The Role of NIH Biomedical Research in Pandemic Influenza Preparedness - MD Fauci, S Anthony - Testimony Before the House Committee on Appropriations …, 2005 - niaid.nih.gov ... of NIH Biomedical Research in Pandemic Influenza Preparedness ... Pasteur) and Chiron,
which have NIAID contracts to ...dose to optimize immunogenicity, as well as ...
[PDF]Many eyes on influenza virus in Asia, anticipating pandemic M Cimons - ASM News, 2005 - Am Soc Microbiol ... How- ever, he adds, ?The dose that gives you ... gives you a response to the seasonal flu.? This dependence ... Fauci says that NIAID plans to test this candidate ... -
[DOC]NIAID ILIs & Influenza Morning Update 10/15/06 A Granados, C Goodman, L Eklund - Eur Respir J, 2006 - ag-security.com ... for any statements made that are the sender's own and not expressly made on behalf
of the NIAID by one of ... Wash Post: Dose of Trouble for Flu-Shot Season ...
NIAID Study Finds Higher Dose of Flu Vaccine Improves Immune Response in the Elderly
There may be a simple way to provide elderly Americans with extra protection against the annual flu virus: give them a higher dose of seasonal flu vaccine. This idea is suggested by the results of a newly reported clinical trial supported by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).
The trial, described in the latest issue of the Archives of Internal Medicine, was conducted by a team of researchers from Baylor College of Medicine in Houston, TX, and sanofi pasteur, the vaccines business of the sanofi-aventis Group in Paris. Led by Dr. Wendy Keitel, M.D., the team conducted the trial at the Baylor Vaccine and Treatment Evaluation Unit, which is one of a network of NIAID-supported sites at university research hospitals across the United States that conduct Phase I and II clinical trials to test and evaluate candidate vaccines for infectious diseases.
NIH Director Elias A. Zerhouni, M.D., notes, “The study results reported by Dr. Keitel and her colleagues are important because they suggest that a higher dose of seasonal influenza vaccine can safely and significantly increase the immune responses of older people.”
“Elderly Americans are among the most vulnerable to serious complications of influenza because they generally have more underlying diseases and weaker immune systems than younger people,” says NIAID Director Anthony S. Fauci, M.D. “These findings are an important first step in developing new strategies to better protect the elderly against influenza-associated hospitalizations and mortality.”
“If you look at people who are dying and going into the hospital during an outbreak of seasonal influenza,” says Dr. Keitel, “the majority of those people are older individuals.”
Influenza accounts for some 36,000 deaths and more than 200,000 hospitalizations every year in the United States. It is among America’s most lethal killers simply because the virus infects so many people--some 5 to 20 percent of the U.S. population every year.
In other influenza vaccine studies, higher antibody levels resulted in better protection against infection. Conversely, decreased antibody production in the elderly can leave them more susceptible to infection and the severe complications of influenza. Helping elderly people increase antibody production should help them fight off influenza infections, and this is exactly what Dr. Keitel and her colleagues set out to test when they began the clinical trial. They hypothesized that elderly people could be given higher doses of vaccine safely and that these higher doses would increase the antibody response and confer increased protection without increasing side effects.
In the study, the investigators randomly assigned 202 adults 65 years of age or older into four equal-sized groups: those receiving the normal dose of vaccine (15 micrograms); twice the normal dose (30 micrograms); four times the normal dose (60 micrograms); or a placebo. The average age of the volunteers was 72.4 years. All study participants were followed for a month post-vaccination to look for any vaccine-related side effects and to collect blood to evaluate antibody responses.
Dr. Keitel and her colleagues found that participants in the high-dose group (60 micrograms) had 44 to 79 percent higher levels of antibody than did those who received the normal dose of vaccine. Higher doses also increased the number of elderly volunteers achieving levels of antibody that have been associated with protection against influenza. Moreover, the vaccine was well-tolerated at all dosage levels. Although the higher doses of vaccine caused more mild side effects at the injection site, there were no significant differences in systemic symptoms such as fever or body aches among the groups.
The successful achievement of higher levels of antibodies in this study suggests that larger doses of vaccine may be a safe and viable way of enhancing protection against influenza among elderly persons. These promising results provide a basis for further evaluation of enhanced potency vaccines in the elderly, says Dr. Keitel.
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.
The National Institutes of Health (NIH)— The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov
###
Reference:
W Keitel et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Archives of Internal Medicine DOI: 10.1001/archinternmed.166.10.1121 (2006).
